BioSight
Companies
ACADIA PHARMACEUTICALS INC logo

ACAD

NASDAQSAN DIEGO, CA
ACADIA PHARMACEUTICALS INC

ACADIA Pharmaceuticals develops drugs targeting neurological and psychiatric disorders. The company has commercialized DAYBUE (trofinetide) and is pursuing additional indications and geographic expansion for existing products while advancing a pipeline of drug candidates through clinical development. ACADIA operates across multiple therapeutic areas with products at various stages from clinical trials through commercialization.

Price history not yet available for ACAD.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar